Onco Wiki / Regimen
MCL: alternating R-CHOP/R-DHAP induction followed by an ASCT pathway (MCL Younger-based)
Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.
Wissensdatenbank für Audit. Vorläufiger klinischer Inhalt: Dies ist kein Rezept. Ein Onkologe muss Originalquellen, Anwendbarkeit und Überprüfungsstatus überprüfen. Vollständige Regeln und Einschränkungen sind in der YAML.
Quelle YAML: Vollständige Aufzeichnung
| Bestandteile | None declared |
|---|
| ID | REG-MCL-INTENSIVE-RDHAP-AUTOSCT |
|---|
| Art | Therapieschema |
|---|
| Status | pending_clinical_signoff |
|---|
| Erkrankungen | None declared |
|---|
| Quellen | SRC-NCCN-BCELL-2025 |
|---|
Anmerkungen
MCL Younger-based alternating induction: R-CHOP cycles 1, 3, 5 and R-DHAP cycles 2, 4, 6. Cisplatin is an essential R-DHAP component and was missing from the prior data. This is not the Nordic MCL2 maxi-CHOP/high-dose cytarabine regimen or a LyMA-style induction. Transplant conditioning and subsequent maintenance are not specified here; alternative conditioning must not inherit trial outcomes automatically. This record does not establish current first-line preference or individualized eligibility.
Evidence for specific statements
These citations cover only the statements and scopes shown. They do not establish clinical approval of this record.
In eviQ MCL R-DHAP, cisplatin is 100 mg/m² by IV infusion over 24 hours on day 1; cytarabine is 2 g/m² per dose by IV infusion over 3 hours twice on day 2, 12 hours apart. R-DHAP occupies cycles 2, 4 and 6, alternating with R-CHOP cycles 1, 3 and 5 at 21-day intervals. These are reference-protocol doses, not individualized dosing permission.
Induction component identity and timing only; not renal dose selection, current treatment preference or whole-record approval.
SRC-EVIQ-MCL-RDHAP-1884 SRC-EVIQ-MCL-RCHOP-1883
eviQ 1884 v6 and 1883 v6 treatment schedules.
The alternating R-CHOP/R-DHAP induction is distinct from Nordic MCL2 and LyMA induction. MCL Younger used a specific conditioning regimen; substituting BEAM or another conditioning regimen introduces uncertainty and does not authorize automatic transfer of trial outcomes.
Protocol identity and conditioning uncertainty only; not transplant prescription, maintenance schedule or efficacy estimate.
SRC-EVIQ-MCL-ALTERNATING-1855
eviQ 1855 v3 Evidence: Nordic MCL2, LyMA and MCL Younger conditioning caveat.
Verwendet von
Anwendungsgebiet
Überwachung
MON-MCL-RCHOP-RDHAP-INDUCTION - MON-MCL-RCHOP-RDHAP-INDUCTION